CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

NCT03517176 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: CEND-1
DRUG: Nab-paclitaxel
DRUG: Gemcitabine

Sponsor

Lisata Therapeutics, Inc.